Bridget Flavin,Denise Wolff,Gaurang Gandhi et al.
Bridget Flavin et al.
Hard-to-control hypertension, comprising uncontrolled and resistant hypertension, is highly prevalent, meaning many patients with hypertension remain at risk of adverse outcomes despite treatment. To discuss the role of managed care in addr...
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis [0.03%]
Bridget Flavin,Denise Wolff,Mike Abdo et al.
Bridget Flavin et al.
Atopic dermatitis (AD), is a chronic, relapsing inflammatory skin disorder that can pose a significant burden to patients and their caregivers and decrease their quality of life. Although substantial advances have been made in the safety an...
Correction Statement [0.03%]
Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council [0.03%]
Foluso Agboola,Shahariar Mohammed Fahim,Grace A Lin et al.
Foluso Agboola et al.
Development of a decision aid to help dually enrolled veterans make informed choices on medication sourcing [0.03%]
Anna Hung,Jadyn Cleary,Ellen B Lawrence et al.
Anna Hung et al.
Background: Veterans enrolled in both Veterans Affairs (VA) health care and Medicare Part D can choose to obtain medications through the VA, Medicare Part D, or both, with each option differing in cost, coverage, and coor...
The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial [0.03%]
Rintu Saju,Jessica M Harwood,Chi-Hong Tseng et al.
Rintu Saju et al.
Background: High-need, high-cost (HNHC) beneficiaries experience life stressors that complicate their medication self-management. Care coordination programs may improve medication-taking behavior, including for chronic co...
Randomized Controlled Trial
Journal of managed care & specialty pharmacy. 2026 May;32(5):540-550. DOI:10.18553/jmcp.2026.32.5.540 2026
Real-world adherence, persistence, and health care resource utilization among people with HIV receiving long-acting cabotegravir plus rilpivirine compared with oral antiretroviral therapy in the United States: The ABOVE Study [0.03%]
Cindy Garris,Maral DerSarkissian,Rose Chang et al.
Cindy Garris et al.
Background: Long-acting cabotegravir + rilpivirine (CAB+RPV LA) is the first US Food and Drug Administration-approved complete long-acting regimen for people with HIV who are virologically suppressed. Long-acting CAB+RPV ...
Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States [0.03%]
Cindy M Chan,Tushita Mayanil,K N Roy Chengappa et al.
Cindy M Chan et al.
Background: Schizophrenia is associated with high treatment nonadherence and economic burden in the United States. Long-acting injectable (LAI) antipsychotics may improve adherence and reduce relapse risk, but comparative...
Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries [0.03%]
Nico Gabriel,Kristi Martin,Emma M Cousin et al.
Nico Gabriel et al.
Background: Prescription drug list prices in the United States far exceed those in peer nations, averaging 278% of non-US prices and 422% for branded products. The Inflation Reduction Act authorized Medicare to negotiate ...
Victoria W Dayer,Ryan N Hansen,Joshua Roth et al.
Victoria W Dayer et al.
Background: Despite demonstrated savings from biosimilars, evidence examining savings experienced by patients is mixed, especially in the commercially insured population. Reference product prices typically decrease after ...